Feature | August 29, 2006| Kim Phelan

This is No Time to Get Cheap

Kim Phelan, Editor

At a pivotal time of advancement in cardiovascular imaging, diagnostics, interventions and therapies, a time when specialty heart hospitals are forming to combat the deadliest disease in America, the federal purse strings are about to be pulled a little tighter in 2007, and rules for these types of narrowly focused hospitals are going to be more stringent.
The Centers for Medicare and Medicaid (CMS) have announced in a final report that specialty hospitals that fail to report their financial structure to the federal government will be fined $10,000 per day. These hospitals will also be required to disclose to patients their financial relationships with physicians, and must treat all emergency cases regardless of patients’ ability to pay. CMS, according to an article published on Modernhealthcare.com, has allowed a federal moratorium on Medicare payments to new specialty hospitals to lapse as of August 8.
But there’s more bad news for cardiologists as well as other physicians.
Doctors are about to take a pay cut as Medicare prepares to reduce physician reimbursement rates by 5.1 percent, a plan scheduled, under current law, to take effect in 2007. But Medicare will spend about $61.5 billion on physician services next year, under the proposed physician fee schedule, Modernhealthcare reports.
The reimbursement landscape may not be lush, but it isn’t entirely bleak either. While investigating some of the latest thinking on ventricular assist devices for a feature story we present on page 58, I learned from Mike Minogue, CEO of Abiomed, that CMS was persuaded last fall to change its view on reimbursing devices used to recover patients’ hearts. According to Minogue, the agency granted approval on Oct. 1, 2005 for heart recovery devices equal to heart transplant, meaning that for the implant and explant of a VAD, the hospital receives a DRG 103, the heart transplantation reimbursement.
I asked a spokesperson for Thoratec whether reimbursement is more favorable today for certain devices than for others, to which she replied: “For cardiologists, reimbursement is consistent regardless of the device implanted. Patient length of stay affects the amount of visits and payment in the inpatient setting.”
Devices and procedures that cardiologists bring to their patients are undeniably expensive. Physicians make heavy decisions every day about treatment path and treatment timing, weighing what’s right for the patient as well as the costs that will be involved. Dr. Leslie Miller at Georgetown University and Washington Hospital told me that doctors must sometimes discern whether patients receiving devices are likely to experience “meaningful recovery.”
In the end, despite the push and pull of reimbursement policies, physicians receive an invaluable reward in exchange for the burdens they carry.
“We are trying to be very good stewards of expensive resource[s],” said Dr. Miller. “We have seen people’s lives totally turned around, and there are very few things in medicine more gratifying than heart transplantation or a successful mechanical device because these people don’t just survive. They can truly regain function capacity, integrating with their families, [even] going back to work — really having a categorical life. And if it is yours, how do you put a dollar value on that?”
You can’t.
Thanks for reading this special TCT edition!

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init